TriLink Biotechnologies said today that it has inked a licensing agreement with Denmark's QuantiBact to offer twisted intercalating nucleic acid, or TINA, modified oligonucleotides.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation, thus improving the sensitivity and specificity of endpoint and real-time PCR, TriLink said. The molecules may be used wherever an enhanced melting temperature is required such as triplex formation, or potentially even gene silencing, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.